NEJM Interview: Peter Ubel on strategies for protecting patients from high out-of-pocket costs for drugs with questionable benefits.
NEJM Interviews
00:00
Financial Implications of FDA Drug Approvals
This chapter examines the gap between FDA drug approval processes and the financial strain new medications place on patients. It advocates for regulatory changes to enhance transparency and inform patients about the costs and effectiveness of approved drugs.
Transcript
Play full episode
